Subtype
Bladder Urothelial Carcinoma
CI-CAN-00004632Explore in graph →
60 active trials5 evidence items
- NCIt
- C39851
- OncoTree
- BLCA
- DOID
- 4006
- UMLS CUI
- C0279680
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004632Explore in graph →
Clinical trials
138 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05946369 | Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer | completed | — | 96 | Ain Shams UniversityOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | completed | Phase 1 | 27 | Celldex TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05833997 | Safety Analysis and Oncological Outcomes in HoLERT vs TURBT | unknown | N/A | 100 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03854721 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | completed | Phase 1 | 6 | Vaxiion TherapeuticsINDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05052372 | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | terminated | — | 2 | xCuresINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT02437370 | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | completed | Phase 1 | 32 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | withdrawn | Phase 1 | 0 | Guru P. SonpavdeOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05139134 | Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival(RESECT) | terminated | Early Phase 1 | 2 | University Health Network, TorontoOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05220124 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | unknown | Phase 4 | 190 | Tianjin Medical University Second HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT04730232 | Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable | unknown | Phase 2 | 63 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05027412 | En Bloc TURBT With Collins Loop vs Conventional TURBT(TURBT) | unknown | N/A | 80 | Hospital Universitario de FuenlabradaOTHER | 1 | Aug 30, 2021 | clinicaltrials |
| NCT04647981 | Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.(Xpert Bladder) | completed | — | 320 | Clinique Beau SoleilOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT04129606 | Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy(TURBT-BP) | unknown | N/A | 300 | Abdelwahab HashemOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT02494635 | Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer | terminated | — | 4 | University of Southern CaliforniaOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02699853 | Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer | terminated | N/A | 1 | University of Southern CaliforniaOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02514408 | Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 0 | Jan 2, 2018 | clinicaltrials |
| NCT03238664 | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Jan 2, 2018 | clinicaltrials |
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03138824 | Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC | unknown | N/A | 100 | Mansoura UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01522820 | Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors | completed | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Oct 4, 2016 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01304173 | Retrospective Chart Review of Valstar | completed | — | 113 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01968928 | The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma | unknown | — | 25 | National Taiwan University HospitalOTHER | 1 | Oct 28, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 4, 2023source: clinicaltrials